The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis: SP + IP PTX trial.
 
Daisuke Kobayashi
Honoraria - Bristol-Myers Squibb Japan; Lilly Japan; ONO PHARMACEUTICAL
 
Ryoji Fukushima
No Relationships to Disclose
 
Mitsuhiko Ota
No Relationships to Disclose
 
Sachio Fushida
Speakers' Bureau - Bristol-Myers Squibb Japan; Lilly Japan; Taiho Pharmaceutical
 
Naoyuki Yamashita
No Relationships to Disclose
 
Kozo Yoshikawa
No Relationships to Disclose
 
Shugo Ueda
No Relationships to Disclose
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Tetsuya Kusumoto
No Relationships to Disclose
 
Takaaki Arigami
No Relationships to Disclose
 
Akio Hidemura
No Relationships to Disclose
 
Takeshi Omori
No Relationships to Disclose
 
Hironori Yamaguchi
No Relationships to Disclose
 
Yasuo Hirono
No Relationships to Disclose
 
Yasushi Tsuji
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Medicon; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kentaro Kishi
No Relationships to Disclose
 
Toshihiko Tomita
No Relationships to Disclose
 
Hironori Ishigami
Honoraria - Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Joji Kitayama
Honoraria - Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Nihon Pharma; Taiho Pharmaceutical (Inst); TERUMO
Travel, Accommodations, Expenses - Taiho Pharmaceutical
 
Yasuhiro Kodera
Honoraria - Abbvie/Pharmacyclics; Asahi Kasei; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien/Medtronic; Hisamitsu Pharmaceutical; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; MSD K.K; Olympus; Ono Pharmaceutical; Otsuka; Sumitomo Group; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Research Funding - Abbott Japan (Inst); Abbvie (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)